The U.S. Food and Drug Administration approved Tenpoint Therapeutics’ Yuvezzi, a dual‑agent ophthalmic solution (carbachol and brimonidine) for adult presbyopia, marking the first FDA‑cleared combination eye drop for the indication. Tenpoint announced a concurrent financing package totaling up to $235 million—$85 million in Series B equity plus a $150 million senior secured term loan—to fund launch and market access activities. Tenpoint positions Yuvezzi as a differentiated, dual‑mechanism alternative to single‑agent topical therapies. The approval and sizable financing de‑risks commercial launch execution and gives the small biotech resources for physician education, distribution, and reimbursement engagement. The decision also highlights the regulatory and commercial pathway viability for specialty ophthalmic therapeutics and signals investor appetite for boutique product launches supported by non‑dilutive debt and venture capital.